Timothy Lymberiou1, Susanne Galuszka1, Grace Lee1, Wei Xu2, Anthony Fyles3, Susie Su2, Thomas G Purdie4, Pamela Catton3, Caroline Chung3, Robert Dinniwell3, Anne Koch3, Wilfred Levin3, Lee Manchul3, Padraig Warde3, Fei-Fei Liu5. 1. Department of Radiation Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada. 2. Division of Biostatistics, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada. 3. Department of Radiation Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada; Department of Radiation Oncology, University of Toronto, Canada. 4. Department of Radiation Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada; Department of Radiation Oncology, University of Toronto, Canada; Techna Institute, University Health Network, Toronto, Canada. 5. Department of Radiation Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada; Department of Radiation Oncology, University of Toronto, Canada. Electronic address: Fei-Fei.Liu@rmp.uhn.on.ca.
Abstract
BACKGROUND AND PURPOSE: This study describes the process and outcomes of breast radiotherapy (RT) quality assurance (QA) rounds, seeking to identify variables associated with plan modifications. MATERIALS AND METHODS: Real-time data were prospectively collected over 2 years. Descriptive statistics determined the proportion of cases requiring no (A), minor (B), or major (C) modifications, which were then subjected to univariate and multivariate analyses. RESULTS: A total of 2223 breast cancer QA cases were reviewed; 47 cases (2.1%) underwent a minor, and 52 cases (2.3%) required a major modification. Common changes included boost, volume, seroma, and bolus. On univariate analysis, regional nodal irradiation (RNI), tumour size, and axillary node dissection were significantly associated with major modifications. Upon multivariate analysis, the only independent predictor was RNI (OR 2.12, p=0.0075). For patients with no RNI, <2 cm tumours, no axillary lymph node dissection, and no boosts (n=420); the likelihood of category C was only 1.4%. CONCLUSIONS: It is feasible to conduct QA review for all breast cancer cases prior to commencing RT. Patients undergoing RNI had a higher likelihood of plan modifications; a group with low risk of modification was identified, which could direct future re-structuring of QA rounds.
BACKGROUND AND PURPOSE: This study describes the process and outcomes of breast radiotherapy (RT) quality assurance (QA) rounds, seeking to identify variables associated with plan modifications. MATERIALS AND METHODS: Real-time data were prospectively collected over 2 years. Descriptive statistics determined the proportion of cases requiring no (A), minor (B), or major (C) modifications, which were then subjected to univariate and multivariate analyses. RESULTS: A total of 2223 breast cancer QA cases were reviewed; 47 cases (2.1%) underwent a minor, and 52 cases (2.3%) required a major modification. Common changes included boost, volume, seroma, and bolus. On univariate analysis, regional nodal irradiation (RNI), tumour size, and axillary node dissection were significantly associated with major modifications. Upon multivariate analysis, the only independent predictor was RNI (OR 2.12, p=0.0075). For patients with no RNI, <2 cm tumours, no axillary lymph node dissection, and no boosts (n=420); the likelihood of category C was only 1.4%. CONCLUSIONS: It is feasible to conduct QA review for all breast cancer cases prior to commencing RT. Patients undergoing RNI had a higher likelihood of plan modifications; a group with low risk of modification was identified, which could direct future re-structuring of QA rounds.
Authors: Murat Surucu; Amishi Bajaj; John C Roeske; Alec M Block; Jennifer Price; William Small; Abhishek A Solanki Journal: Adv Radiat Oncol Date: 2019-03-21
Authors: E Martin-Garcia; F Celada-Álvarez; M J Pérez-Calatayud; M Rodriguez-Pla; O Prato-Carreño; D Farga-Albiol; O Pons-Llanas; S Roldán-Ortega; E Collado-Ballesteros; F J Martinez-Arcelus; Y Bernisz-Diaz; V A Macias; J Chimeno; J Gimeno-Olmos; F Lliso; V Carmona; J C Ruiz; J Pérez-Calatayud; A Tormo-Micó; A J Conde-Moreno Journal: Clin Transl Oncol Date: 2020-06-15 Impact factor: 3.405
Authors: Nicole Harnett; Kate Bak; Elizabeth Lockhart; Michelle Ang; Laura Zychla; Eric Gutierrez; Padraig Warde Journal: J Med Radiat Sci Date: 2018-06
Authors: Anis Ahmad; Lakshmi Santanam; Abhishek A Solanki; Laura Padilla; Erina Vlashi; Patrizia Guerrieri; Michael M Dominello; Jay Burmeister; Michael C Joiner Journal: J Appl Clin Med Phys Date: 2020-11-24 Impact factor: 2.243